Company intelligence / Profile preview
PhagePro
Boston, Massachusetts, United Statesphageproinc.com ↗
- Ownership
- Private
- Employees
- ~5
- Development stage
- Preclinical
01
Overview
PhagePro’s lead product, ProphaLytic-Vc, has demonstrated promise in preclinical studies as an oral bacteriophage preparation targeting epidemic cholera strains. The company aims to prevent household and community transmission of cholera with a rapidly acting prophylactic treatment. Clinical trials are being prepared but have not yet commenced as of the latest available information.
- Therapeutic areas
- Infectious Diseases
- Modalities
- Bacteriophage-based therapeutics (phages)
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Collaborations with external partners for formulation optimization and manufacturing CROs mentioned; specific partner names not disclosed.
Beyond the preview
Go deeper on PhagePro.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PhagePro.